How the SCOTUS decision to gut the FTC could help biopharma companies

The Supreme Court on Thursday unanimously decided to remove the Federal Trade Commission’s powers to secure billions of dollars in relief for consumers in a wide variety of cases, leaving the door open for biopharma companies to quickly end certain cases involving anticompetitive practices.

In essence, the ruling would prohibit...

Click to view original post